LIA
VKTX icon

Limestone Investment Advisors’s Viking Therapeutics VKTX Stock Holding History

Limestone Investment Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-43,207
Closed -$1.52M – 556
2025
Q4 		$1.52M Hold
43,207
– – 0.15% 118
2025
Q3 		$1.14M Hold
43,207
– – 0.09% 164
2025
Q2 		$1.14M Buy
+43,207
New +$1.14M 0.1% 164

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Limestone Investment Advisors's VKTX Position: Q1 2026 in Review

Limestone Investment Advisors sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 43,207 shares — an estimated $1.52M sold.

Limestone Investment Advisors first reported a position in VKTX in Q2 2025 and held it in 3 quarters. The position peaked at $1.52M in Q4 2025. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Limestone Investment Advisors reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Limestone Investment Advisors sold 43,207 Viking Therapeutics shares in Q1 2026, an estimated $1.52M.
  • Limestone Investment Advisors first reported a position in Viking Therapeutics in Q2 2025 and held it in 3 quarters.
  • Limestone Investment Advisors's Viking Therapeutics position peaked at $1.52M in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Limestone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.